Xue Yang

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Jianqiong Zhang · 2 shared papers, 2025 · strength 0.43
   • Paper Enhancing the tissue penetration to improve sonodynamic immunotherapy for pancreatic ductal adenocarcinoma using membra… DOI 10.1007/s00259-024-06952-y↗
   • Paper Engineering a spatiotemporal macrophage circuit via STING phase separation to override immune suppression in pancreatic… DOI 10.1073/pnas.2504718122↗
2. Shenghong Ju · 2 shared papers, 2025 · strength 0.43
   • Paper Enhancing the tissue penetration to improve sonodynamic immunotherapy for pancreatic ductal adenocarcinoma using membra… DOI 10.1007/s00259-024-06952-y↗
   • Paper Engineering a spatiotemporal macrophage circuit via STING phase separation to override immune suppression in pancreatic… DOI 10.1073/pnas.2504718122↗
3. Jiawei Du · 1 shared paper, 2025 · strength 0.22
   • Paper Enhancing the tissue penetration to improve sonodynamic immunotherapy for pancreatic ductal adenocarcinoma using membra… DOI 10.1007/s00259-024-06952-y↗
4. Xiaoyuan Shawn Chen · 1 shared paper, 2025 · strength 0.21
   • Paper Engineering a spatiotemporal macrophage circuit via STING phase separation to override immune suppression in pancreatic… DOI 10.1073/pnas.2504718122↗
5. Ben Zhao · 1 shared paper, 2025 · strength 0.21
   • Paper Engineering a spatiotemporal macrophage circuit via STING phase separation to override immune suppression in pancreatic… DOI 10.1073/pnas.2504718122↗
6. Yuling Sun · 1 shared paper, 2025 · strength 0.21
   • Paper Engineering a spatiotemporal macrophage circuit via STING phase separation to override immune suppression in pancreatic… DOI 10.1073/pnas.2504718122↗
7. Huan Wang · 1 shared paper, 2025 · strength 0.18
   • Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4↗
8. Xiaoyu Yin · 1 shared paper, 2025 · strength 0.18
   • Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4↗
9. Tongsen Zheng · 1 shared paper, 2025 · strength 0.18
   • Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4↗
10. Xianze Wang · 1 shared paper, 2025 · strength 0.18
    • Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4↗
11. Qiang Xu · 1 shared paper, 2025 · strength 0.18
    • Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4↗
12. Chuntao Gao · 1 shared paper, 2025 · strength 0.18
    • Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4↗
13. Zhihua Li · 1 shared paper, 2025 · strength 0.18
    • Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4↗
14. Tao Xia · 1 shared paper, 2025 · strength 0.18
    • Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4↗
15. Yuejuan Cheng · 1 shared paper, 2025 · strength 0.18
    • Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4↗
16. Heshui Wu · 1 shared paper, 2025 · strength 0.18
    • Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4↗
17. Rufu Chen · 1 shared paper, 2025 · strength 0.18
    • Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4↗
18. Deliang Fu · 1 shared paper, 2025 · strength 0.18
    • Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4↗
19. Wenming Wu · 1 shared paper, 2025 · strength 0.18
    • Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4↗
20. Maohua Cai · 1 shared paper, 2020 · strength 0.13
    • Paper Role of Treg/Th17 Imbalance, Microbiota and miRNAs in Pancreatic Cancer: Therapeutic Options. DOI 10.1615/critrevimmunol.2020033631↗
21. Ying‐Yu Ma · 1 shared paper, 2020 · strength 0.13
    • Paper Role of Treg/Th17 Imbalance, Microbiota and miRNAs in Pancreatic Cancer: Therapeutic Options. DOI 10.1615/critrevimmunol.2020033631↗
22. Luo‐Qin Fu · 1 shared paper, 2020 · strength 0.13
    • Paper Role of Treg/Th17 Imbalance, Microbiota and miRNAs in Pancreatic Cancer: Therapeutic Options. DOI 10.1615/critrevimmunol.2020033631↗
23. Weiwei Jin · 1 shared paper, 2020 · strength 0.13
    • Paper Role of Treg/Th17 Imbalance, Microbiota and miRNAs in Pancreatic Cancer: Therapeutic Options. DOI 10.1615/critrevimmunol.2020033631↗
24. Yiping Mou · 1 shared paper, 2020 · strength 0.13
    • Paper Role of Treg/Th17 Imbalance, Microbiota and miRNAs in Pancreatic Cancer: Therapeutic Options. DOI 10.1615/critrevimmunol.2020033631↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.